InvisiShield’s engineered, long-acting, intranasal antibody-fusion protein platform is a revolutionary shift in the prevention of respiratory virus infection, transmission, and disease. Our preventives are designed to work above and beyond what vaccines and systemic antibodies, or antivirals, can do. By concentrating and residing durably on the mucosal surface, where respiratory viruses initiate infection, our preventives both block infection in healthy individuals and reduce, or completely halt, viral shedding in those already infected.

Beyond these transformative prophylaxis mechanisms, the technology offers several advantageous properties for the safe, affordable, proactive delivery of household, community, and population-level protection.